Phreesia (NYSE:PHR) Insider Evan Roberts Sells 6,317 Shares of Stock

Phreesia, Inc. (NYSE:PHR) insider Evan Roberts sold 6,317 shares of Phreesia stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider directly owned 834,632 shares in the company, valued at $14,197,090.32. This trade represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Friday, October 17th, Evan Roberts sold 1,888 shares of Phreesia stock. The shares were sold at an average price of $22.36, for a total transaction of $42,215.68.

Phreesia Stock Performance

Shares of Phreesia stock opened at $17.14 on Tuesday. The company’s 50 day moving average price is $18.84 and its two-hundred day moving average price is $23.61. The firm has a market capitalization of $1.03 billion, a P/E ratio of -171.33 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia, Inc. has a fifty-two week low of $15.41 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue was up 12.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.25) EPS. On average, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. Raymond James Financial Inc. grew its position in shares of Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after acquiring an additional 375 shares during the period. Diversified Trust Co lifted its stake in Phreesia by 1.0% in the second quarter. Diversified Trust Co now owns 45,042 shares of the company’s stock valued at $1,282,000 after purchasing an additional 426 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Phreesia by 2.8% during the second quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock valued at $569,000 after purchasing an additional 540 shares during the period. Oppenheimer Asset Management Inc. increased its position in Phreesia by 9.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company’s stock worth $251,000 after buying an additional 792 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Phreesia by 1.3% in the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after buying an additional 812 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Neutral Sentiment: Royal Bank of Canada initiated coverage on Phreesia. Initiations can increase visibility and trading, but the report does not appear to include a widely circulated bullish or bearish revision that would clearly move consensus. Royal Bank Of Canada Initiates Coverage on Phreesia (NYSE:PHR)
• Negative Sentiment: Citigroup reduced its price target for PHR to $25.00. A lower target from a major broker can weigh on sentiment and reduce upside expectations among investors who follow sell‑side guidance. Citigroup Cuts Phreesia (NYSE:PHR) Price Target to $25.00
• Negative Sentiment: Multiple senior insiders sold shares on Jan. 8 (including the General Counsel, CFO, other officers). Collective insider selling at ~ $17.01 per share (individual Form 4s below) increases float and can be interpreted by some investors as reduced insider conviction, pressuring the stock short‑term. Filings: Allison C. Hoffman (Form 4) SEC Form 4 – Allison C. Hoffman, Balaji Gandhi (CFO) SEC Form 4 – Balaji Gandhi, Evan Roberts SEC Form 4 – Evan Roberts, David Linetsky SEC Form 4 – David Linetsky, Amy Beth Vanduyn SEC Form 4 – Amy Beth Vanduyn, Yvonne Hui SEC Form 4 – Yvonne Hui

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a report on Monday, December 8th. JPMorgan Chase & Co. dropped their price target on shares of Phreesia from $32.00 to $29.00 and set an “overweight” rating for the company in a research note on Tuesday, December 9th. Barclays reduced their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 16th. Truist Financial set a $24.00 target price on Phreesia in a research report on Thursday. Finally, Mizuho reduced their price target on Phreesia from $36.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 10th. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.